Krystal Biotech price target raised to $327 from $206 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Krystal Biotech (KRYS) to $327 from $206 and keeps a Buy rating on the shares. Krystal Biotech is positioning for near-term growth with three registrational programs, KB803, KB801, and KB407, targeting potential 2028 launches, the analyst tells investors in a research note. Ophthalmic programs are viewed as de-risked and highly leverageable on existing Vyjuvek infrastructure, while KB407 shows promise in cystic fibrosis but requires FEV1 data for conviction, the firm says.